Tags

Type your tag names separated by a space and hit enter

Melatonin: from basic research to cancer treatment clinics.
J Clin Oncol. 2002 May 15; 20(10):2575-601.JC

Abstract

Melatonin, the chief secretory product of the pineal gland, is a direct free radical scavenger, an indirect antioxidant, as well as an important immunomodulatory agent. In both in vitro and in vivo investigations, melatonin protected healthy cells from radiation-induced and chemotherapeutic drug-induced toxicity. Furthermore, several clinical studies have demonstrated the potential of melatonin, either alone or in combination with traditional therapy, to yield a favorable efficacy to toxicity ratio in the treatment of human cancers. This study reviews the literature from laboratory investigations that document the antioxidant and oncostatic actions of melatonin and summarizes the evidence regarding the potential use of melatonin in cancer treatment. This study also provides rationale for the design of larger translational research-based clinical trials.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Vijayalaxmi
Departments of Radiation Oncology, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. vijay@uthscsa.edu
Thomas CR
No affiliation info available
Reiter RJ
No affiliation info available
Herman TS
No affiliation info available

MeSH

AnimalsAntioxidantsClinical Trials as TopicDisease Models, AnimalFree Radical ScavengersHumansMelatoninNeoplasms

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12011138

Clinical Trial Links

Circadian as A Prognostic Factor For Radiation Response in Cervical Cancer

Citation

Vijayalaxmi, , et al. "Melatonin: From Basic Research to Cancer Treatment Clinics." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 20, no. 10, 2002, pp. 2575-601.
Vijayalaxmi , Thomas CR, Reiter RJ, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20(10):2575-601.
Vijayalaxmi, ., Thomas, C. R., Reiter, R. J., & Herman, T. S. (2002). Melatonin: from basic research to cancer treatment clinics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 20(10), 2575-601.
Vijayalaxmi , et al. Melatonin: From Basic Research to Cancer Treatment Clinics. J Clin Oncol. 2002 May 15;20(10):2575-601. PubMed PMID: 12011138.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Melatonin: from basic research to cancer treatment clinics. AU - Vijayalaxmi,, AU - Thomas,Charles R,Jr AU - Reiter,Russel J, AU - Herman,Terence S, PY - 2002/5/16/pubmed PY - 2002/6/6/medline PY - 2002/5/16/entrez SP - 2575 EP - 601 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 20 IS - 10 N2 - Melatonin, the chief secretory product of the pineal gland, is a direct free radical scavenger, an indirect antioxidant, as well as an important immunomodulatory agent. In both in vitro and in vivo investigations, melatonin protected healthy cells from radiation-induced and chemotherapeutic drug-induced toxicity. Furthermore, several clinical studies have demonstrated the potential of melatonin, either alone or in combination with traditional therapy, to yield a favorable efficacy to toxicity ratio in the treatment of human cancers. This study reviews the literature from laboratory investigations that document the antioxidant and oncostatic actions of melatonin and summarizes the evidence regarding the potential use of melatonin in cancer treatment. This study also provides rationale for the design of larger translational research-based clinical trials. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/12011138/Melatonin:_from_basic_research_to_cancer_treatment_clinics_ L2 - https://ascopubs.org/doi/10.1200/JCO.2002.11.004?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -